AA
CTNM

ALPS Advisors’s Contineum Therapeutics CTNM Stock Holding History

ALPS Advisors’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$544K Buy
+33,210
New +$435K ﹤0.01% 946

Other funds holding CTNM

RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
IFG
Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM

ALPS Advisors's CTNM Position: Q2 2026 in Review

ALPS Advisors opened a new position in Contineum Therapeutics (CTNM) in Q2 2026: 33,210 shares worth $544K. The stake represents ﹤0.01% of the portfolio and ranks #946 among its holdings.

9 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • ALPS Advisors held 33,210 shares of Contineum Therapeutics worth $544K as of Q2 2026.
  • Contineum Therapeutics was a new ALPS Advisors position in Q2 2026.
  • Contineum Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #946 holding.
  • 9 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.